Medicaid GLP-1 Coverage by State (2026): All 50 States, Verified

Only 13 state Medicaid fee-for-service programs cover GLP-1 medications for obesity treatment as of 2026 — and that number dropped from 16 after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage on January 1. Roughly 80% of adult Medicaid enrollees live in states with no obesity GLP-1 pathway right now.

But "not covered for weight loss" is not the same thing as "no path at all." Every state Medicaid program is federally required to cover GLP-1s prescribed for type 2 diabetes. Since 2024, the rules changed for additional indications — Wegovy for cardiovascular risk reduction, Zepbound for obstructive sleep apnea, Wegovy for MASH. Children under 21 have a separate federal protection (EPSDT) that most pages don't mention.

Sources: KFF Medicaid Coverage of and Spending on GLP-1s (Jan 2026); The RX Index Coverage Reach calculation based on CMS enrollment data; state Medicaid bulletins.

If any of those sound familiar, you're in the right place. The system is genuinely confusing — and it's changing faster than most coverage guides keep up with. That's why we verify this page monthly and publish every source, every change date, and a downloadable dataset you can audit yourself.

Why your answer may change depending on fee-for-service vs. managed care

About 78% of Medicaid beneficiaries nationally are enrolled in comprehensive managed care (MCOs), not fee-for-service (FFS). The 50-state table above is based on FFS coverage — the baseline policy that each state sets. But your actual coverage may differ depending on which plan you're in.

Fee-for-service means the state Medicaid agency pays providers directly. The state's preferred drug list (PDL) is what determines your coverage.

Managed care means a private insurance company (the MCO) manages your Medicaid benefits under contract with the state. MCOs have their own formularies and prior authorization criteria. In some states, the MCO may cover drugs the FFS program doesn't — or vice versa.

Don't stop at the state answer — use this checklist

Before you conclude that Medicaid won't cover your GLP-1, verify all five of these:

1. 1Which type of Medicaid do you have? Check your Medicaid card. If it names a company (Aetna Better Health, Anthem MediBlue, Centene, Molina, UnitedHealthcare, etc.), you're in managed care.
2. 2What does your MCO's formulary say? Call the number on the back of your card and ask specifically: "Is [drug name] on your preferred drug list for [your indication]?"
3. 3What indication is your doctor using? "Obesity" vs. "cardiovascular risk reduction" vs. "type 2 diabetes" can produce completely different answers from the same plan.
4. 4Has the formulary been updated recently? MCOs update formularies quarterly. A "no" from six months ago may not be current.
5. 5Is prior authorization required? Even when covered, almost every plan requires PA for GLP-1s. Ask what documentation is needed before your doctor submits.

Here's a script you can use when you call:

Write down the name of the person you speak with, the date, and what they tell you.

Which states changed Medicaid GLP-1 coverage most recently?

Coverage is moving fast — and mostly in the wrong direction. Nine states changed coverage status in the last 12 months, affecting roughly 35% of adult Medicaid enrollees.

Why are states cutting GLP-1 coverage?

It's not because the drugs don't work. States are cutting coverage because the math broke.

KFF data tells the story clearly: Medicaid GLP-1 prescriptions rose from about 1 million in 2019 to over 8 million in 2024 — an eightfold increase. Gross spending rose from about $1 billion in 2019 to nearly $9 billion in 2024. Even accounting for manufacturer rebates that typically reduce costs by about 40%, that's an enormous budget line that grew faster than almost anyone projected.

GLP-1s went from roughly 0% of all Medicaid prescriptions in 2019 to about 1% in 2024 — a tiny share of total prescriptions — but they now account for over 8% of all Medicaid prescription drug spending before rebates. Pennsylvania's numbers illustrate this at the state level: GLP-1 costs grew from 5% of total Medicaid drug spending in 2022 to 22% in 2025.

This isn't about whether GLP-1s are effective. The evidence is clear that they are. It's about whether state budgets can absorb the cost at current utilization rates — especially with federal Medicaid spending cuts from the 2025 reconciliation law adding additional pressure. Nearly 40% of adults on Medicaid have obesity, which means the potential demand is enormous. That's the core tension.

Sources: KFF Medicaid Coverage of and Spending on GLP-1s (Jan 2026); PA DHS data per Philadelphia Inquirer (April 10, 2026); MACPAC enrollment data.

Will the CMS BALANCE Model change Medicaid GLP-1 coverage in your state?

Possibly — and the timeline is now. But it's not automatic, and it's not a guarantee.

Which states will participate?

As of April 10, 2026, CMS has not published a list of participating states. States that already cover GLP-1s for obesity are natural candidates. States that recently eliminated coverage could rejoin under BALANCE if the negotiated pricing makes it budget-feasible. Several states — including Texas, Florida, Georgia, and Ohio — were reportedly considering expansion in KFF's earlier surveys.

What BALANCE means for you

• If your state joins: You may gain coverage starting as early as May 2026, with standardized PA criteria and a lifestyle support program at no cost.
• If your state doesn't join: Nothing changes. Your current coverage status stays in place.
• If you're already covered: You may see lower out-of-pocket costs and access to the lifestyle program.

The honest assessment: BALANCE is promising but voluntary. States facing budget pressure may not opt in even at lower prices, because the volume of eligible enrollees could still make total spending unmanageable. We'll know more by summer 2026.

Sources: CMS BALANCE Model page (updated Mar 2026); CMS BALANCE RFA (Dec 2025); KFF "What to Know About the BALANCE Model" (Mar 2026). For a deeper breakdown, see our full guide: CMS BALANCE Model GLP-1 Explained.

What do I do if my state Medicaid says no?

A denial is not the end. It's the start of a decision tree. Your next step depends on why you were denied and what your specific situation is.

If Medicaid won't cover it: your best next routes

This section is for readers who've worked through the steps above and determined that Medicaid coverage genuinely isn't available in their situation. We're not going to pretend this is ideal — it's not. But we're also not going to leave you without a path forward.

If you need help with prior authorization or insurance navigation

Sometimes the issue isn't that coverage doesn't exist — it's that the paperwork wasn't done right, or a covered indication wasn't explored.

• → How to Get Insurance to Cover GLP-1 Medications — our full guide to PA strategy, appeal letters, and covered indication routing
• → Best GLP-1 Providers That Help With Prior Authorization — providers that handle PA on your behalf

If you need an affordable cash-pay path

Compounded semaglutide is available through licensed telehealth providers at prices dramatically lower than brand-name medications. These programs don't bill Medicaid — they're cash-pay, so there's no PA, no denial, no appeals process. Compounded medications are prepared by licensed pharmacies but are not FDA-approved products. They are legal when prescribed by a licensed provider and dispensed by a licensed pharmacy — but they are not the same as brand-name Wegovy or Zepbound. Prices typically range from $99–$299/month.

• → GLP-1 Cost Without Insurance: All Your Options — our full pricing breakdown across all major telehealth providers

If you want FDA-approved medication at a lower cash price

Ro offers FDA-approved GLP-1 medications including Wegovy (injectable and pill), Zepbound, and Foundayo (orforglipron) — an oral GLP-1 approved April 2026 for chronic weight management. Their Ro Body membership starts at $39 for the first month, then as low as $74/month with an annual plan paid upfront — medication costs are separate. Ro works with commercial insurance for prior authorization on FDA-approved medications but does not currently coordinate coverage for government insurance plans like Medicaid. For Medicaid enrollees who also have a separate commercial plan, or who want to explore the FDA-approved cash-pay route, Ro is worth checking.

If you're not sure which path is right for you

The people who get stuck are the ones who stop after a single "no." The people who get started are the ones who find the path that actually fits.

How we verified every state in this tracker

We built this tracker because we couldn't find one that combined state-level coverage, diagnosis pathway exceptions, recent changes, and actionable next steps in one verified resource.

Source hierarchy

Our verification follows this priority order:

Coverage Reach methodology

Coverage Reach = (adult Medicaid enrollees in states with FFS obesity GLP-1 coverage ÷ total adult Medicaid enrollees nationally) × 100. Using CMS Medicaid enrollment data: ~7.8 million out of ~39.5 million adult Medicaid enrollees = 19.7%.

Limitations

• MCO formularies may differ from FFS in ways we haven't captured for every state and plan
• We verify monthly, not daily — a state could change policy between verification cycles
• BALANCE participation will change the landscape once states begin joining; we'll update as participation is confirmed
• States marked with ⚠️ need additional verification against their current PDL
• We do not have staffed reporters in all 50 states — our verification relies on public documents, official bulletins, and published reporting

Download and audit

We publish the raw data behind this tracker as a downloadable CSV and maintain a public GitHub repository.

Medicaid GLP-1 Coverage by State: FAQ